Frontier Pharma First-In-Class Innovation in Hematological Cancers First-in-Class Innovation in Hematological Cancers Clique para ler
  • Comentários

Frontier Pharma First-In-Class Innovation in Hematological Cancers

First-in-Class Innovation in Hematological Cancers

Publicado no e em "Negócios", idioma — English. 6 páginas.
The report assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Mais
Summary The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Mais
Mostrar Tags
Assine GRÁTIS